Evidence map›Paper›PMID 24824548›Full record

Trial reportDiabetes care2014

Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes.

Ronald B Goldberg, Marinella G Temprosa, Kieren J Mather, Trevor J Orchard, Abbas E Kitabchi, Karol E Watson, Diabetes Prevention Program Research Group

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Ronald B GoldbergDiabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL dppmail@bsc.gwu.edu.
Marinella G TemprosaThe Biostatistics Center, The George Washington University, Rockville, MD.
Kieren J MatherDivision of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, IN.
Trevor J OrchardDiabetes and Lipid Research Building, University of Pittsburgh, Pittsburgh, PA.
Abbas E KitabchiDivision of Endocrinology, University of Tennessee, Memphis, TN.
Karol E WatsonUniversity of California, Los Angeles, Alhambra, CA.
Diabetes Prevention Program Research Group
George Washington University · USIndiana University – Purdue University Indianapolis · USUniversity of California, Los Angeles · USUniversity of Miami · USUniversity of Pittsburgh · USUniversity of Tennessee Health Science Center · US

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Julie Mathieu · 1986 to 2026
$41.4M
Post DPP Followup StudyU01DK048406 · NIDDK · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI DE GROOT, MARY K. · 1994 to 2021
$9.1M
NIDDK NIH HHS P30 DK017047NIDDK NIH HHS U01 DK048406
6 · The paper itself

Abstract

objectiveWe evaluate whether lifestyle and metformin interventions used to prevent diabetes have durable effects on markers of inflammation and coagulation and whether the effects are influenced by the development of diabetes. RESEARCH DESIGN AND

methodsThe Diabetes Prevention Program was a controlled clinical trial of 3,234 subjects at high risk for diabetes who were randomized to lifestyle, metformin, or placebo interventions for 3.4 years. Diabetes was diagnosed semiannually by fasting glucose and annually by oral glucose tolerance testing. In addition to baseline testing, anthropometry was performed every 6 months; fasting insulin yearly; and hs-CRP, tissue plasminogen activator (tPA), and fibrinogen at 1 year and end of study (EOS).

resultsCRP and tPA levels were unchanged in the placebo group but fell in the lifestyle and metformin groups at 1 year and remained lower at EOS. These reductions were not seen in those who developed diabetes over the course of the study despite intervention. Fibrinogen was lower at 1 year in the lifestyle group. Differences in weight and weight change explained most of the influence of diabetes on the CRP response in the lifestyle group, but only partly in the placebo and metformin groups. Weight, insulin sensitivity, and hyperglycemia differences each accounted for the influence of diabetes on the tPA response.

conclusionsLifestyle and metformin interventions have durable effects to lower hs-CRP and tPA. Incident diabetes prevented these improvements, and this was accounted for by differences in weight, insulin resistance, and glucose levels.

Indexed as

Life StyleAdultAgedAged, 80 and overBody WeightC-Reactive ProteinDiabetes Mellitus, Type 2FemaleGlucose Tolerance TestHumansHypoglycemic AgentsInsulinInsulin ResistanceMaleMetforminMiddle AgedC-Reactive ProteinHypoglycemic AgentsInsulinMetforminTissue Plasminogen Activator

Identifiers

PMID24824548
PMCPMC4113172
OpenAlexW2140831325

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.